HK1042252B - 混合血管緊張素轉換酵素抑制劑及環氧化甾醛甾酮對抗劑治療心血管疾病 - Google Patents

混合血管緊張素轉換酵素抑制劑及環氧化甾醛甾酮對抗劑治療心血管疾病

Info

Publication number
HK1042252B
HK1042252B HK02104154.2A HK02104154A HK1042252B HK 1042252 B HK1042252 B HK 1042252B HK 02104154 A HK02104154 A HK 02104154A HK 1042252 B HK1042252 B HK 1042252B
Authority
HK
Hong Kong
Prior art keywords
epoxy
treatment
combination therapy
cardiovascular disease
converting enzyme
Prior art date
Application number
HK02104154.2A
Other languages
English (en)
Other versions
HK1042252A1 (en
Inventor
C Alexander John
Roniker Barbara
Desai Subhash
Original Assignee
Gd Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gd Searle Llc filed Critical Gd Searle Llc
Publication of HK1042252A1 publication Critical patent/HK1042252A1/xx
Publication of HK1042252B publication Critical patent/HK1042252B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
HK02104154.2A 1999-03-05 2002-05-31 混合血管緊張素轉換酵素抑制劑及環氧化甾醛甾酮對抗劑治療心血管疾病 HK1042252B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12297799P 1999-03-05 1999-03-05
PCT/US2000/005633 WO2000051642A1 (en) 1999-03-05 2000-03-03 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Publications (2)

Publication Number Publication Date
HK1042252A1 HK1042252A1 (en) 2002-08-09
HK1042252B true HK1042252B (zh) 2004-04-23

Family

ID=22406014

Family Applications (2)

Application Number Title Priority Date Filing Date
HK02104154.2A HK1042252B (zh) 1999-03-05 2002-05-31 混合血管緊張素轉換酵素抑制劑及環氧化甾醛甾酮對抗劑治療心血管疾病
HK04104294A HK1061200A1 (en) 1999-03-05 2004-06-14 Combination therapy of angiotensin converting enzyme inhibitor and epoxa-steroidal aldosterone antagonist for treatment of cardiovascular disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK04104294A HK1061200A1 (en) 1999-03-05 2004-06-14 Combination therapy of angiotensin converting enzyme inhibitor and epoxa-steroidal aldosterone antagonist for treatment of cardiovascular disease

Country Status (24)

Country Link
US (1) US20040077611A1 (zh)
EP (2) EP1165136B1 (zh)
JP (1) JP2002538172A (zh)
KR (1) KR100580286B1 (zh)
CN (1) CN1229141C (zh)
AR (1) AR029155A1 (zh)
AT (2) ATE249242T1 (zh)
AU (2) AU778559B2 (zh)
BR (1) BR0008781A (zh)
CA (1) CA2364169A1 (zh)
DE (2) DE60024335T2 (zh)
DK (2) DK1382351T3 (zh)
EA (1) EA004064B1 (zh)
ES (2) ES2250803T3 (zh)
HK (2) HK1042252B (zh)
HU (1) HUP0200519A2 (zh)
IL (2) IL145237A0 (zh)
MX (1) MXPA01009035A (zh)
NZ (1) NZ514205A (zh)
PT (1) PT1165136E (zh)
SI (1) SI1165136T1 (zh)
TR (1) TR200102581T2 (zh)
WO (1) WO2000051642A1 (zh)
ZA (1) ZA200107779B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1505072A3 (en) * 1999-12-08 2006-06-21 Pharmacia Corporation Eplerenone crystalline form exhiniting enhanced dissolution rate
EP1580193A3 (en) * 1999-12-08 2010-06-23 Pharmacia Corporation Eplerenone crystalline form
AU2041101A (en) * 1999-12-08 2001-06-18 Pharmacia Corporation Eplerenone crystalline form
AU784946B2 (en) * 1999-12-08 2006-08-03 Pharmacia Corporation Eplerenone crystalline form exhibiting enhanced dissolution rate
US20010039262A1 (en) * 2000-04-26 2001-11-08 Balaji Venkataraman Methods and compositions for the treatment of cardiac indications
DE60114027T2 (de) * 2000-08-28 2006-07-13 Pharmacia Corp. Verwendung von einem aldosteron-rezeptor-antagonisten zur verbesserung der kognitiven funktion
WO2006119779A2 (en) * 2005-05-10 2006-11-16 Lifecycle Pharma A/S A pharmaceutical composition comprising an aldosterone antagonist in form of solid solution
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
US20070112593A1 (en) * 2005-11-14 2007-05-17 Rxcera Pharmaceutical, Inc. Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20100318371A1 (en) * 2009-06-11 2010-12-16 Halliburton Energy Services, Inc. Comprehensive hazard evaluation system and method for chemicals and products
US20150297629A1 (en) * 2012-07-27 2015-10-22 Isis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
CN106267147A (zh) * 2015-06-10 2017-01-04 上药东英（江苏）药业有限公司 一种复方降压药物组合物
BR122020023854B1 (pt) 2015-10-08 2022-11-29 Ionis Pharmaceuticals, Inc Composto compreendendo oligonucleotídeo modificado e seu uso, uso do oligonucleotídeo modificado, composição e seu uso
JP2023549563A (ja) 2020-11-18 2023-11-27 アイオーニス ファーマシューティカルズ， インコーポレーテッド アンジオテンシノーゲン発現を調節するための化合物及び方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6039296A (en) * 1995-06-07 1996-12-30 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldoste rone antagonist
JPH11507627A (ja) * 1995-06-07 1999-07-06 ジー．ディー．サール アンド カンパニー 充血性心不全症を処置するためのエポキシ−ステロイド系アルドステロン拮抗物質とアンギオテンシンｉｉ拮抗物質との組合せ治療

Also Published As

Publication number Publication date
IL145237A0 (en) 2002-06-30
DE60005159D1 (de) 2003-10-16
ATE249242T1 (de) 2003-09-15
DE60024335T2 (de) 2006-08-03
HK1042252A1 (en) 2002-08-09
PT1165136E (pt) 2004-02-27
EA004064B1 (ru) 2003-12-25
TR200102581T2 (tr) 2002-04-22
EA200100951A1 (ru) 2002-04-25
ES2206204T3 (es) 2004-05-16
DK1165136T3 (da) 2004-01-12
WO2000051642A1 (en) 2000-09-08
IL145237A (en) 2006-08-01
ES2250803T3 (es) 2006-04-16
EP1382351B8 (en) 2006-03-08
CN1229141C (zh) 2005-11-30
SI1165136T1 (en) 2004-02-29
EP1165136B1 (en) 2003-09-10
CN1372475A (zh) 2002-10-02
ZA200107779B (en) 2002-12-20
DK1382351T3 (da) 2006-01-23
CA2364169A1 (en) 2000-09-08
AR029155A1 (es) 2003-06-18
EP1382351A1 (en) 2004-01-21
EP1165136A1 (en) 2002-01-02
BR0008781A (pt) 2002-07-02
HK1061200A1 (en) 2004-09-10
MXPA01009035A (es) 2004-08-12
HUP0200519A2 (hu) 2002-07-29
ATE310537T1 (de) 2005-12-15
EP1382351B1 (en) 2005-11-23
AU2005201045A1 (en) 2005-04-07
KR20010108319A (ko) 2001-12-07
DE60005159T2 (de) 2004-07-22
AU3394500A (en) 2000-09-21
KR100580286B1 (ko) 2006-05-16
NZ514205A (en) 2004-07-30
JP2002538172A (ja) 2002-11-12
US20040077611A1 (en) 2004-04-22
DE60024335D1 (de) 2005-12-29
AU778559B2 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
PL348198A1 (en) Combination therapy of angiotensin converting enzyme inhibitor and aldosterone antagonist for reducing morbidity and mortality from cardiovascular disease
HK1042252A1 (en) Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
EP1228061A4 (en) DIPEPTIDYL PEPTIDASE IV INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF
HK1048247A1 (en) Stable carotene-xanthophyll beadlet compositions and methods of use
IL153937A0 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
EP1227821A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR USE THEREOF
EP1604664A4 (en) MEDICAMENT FOR THE PREVENTION AND TREATMENT OF ARTERIOSCLEROSIS AND BLOOD HIGH PRESSURE
AU5739800A (en) Method for direct diagnosis and treatment of pain of muscular origin
AU3270301A (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
IL124253A (en) Fixed-dose combination of an angiotensin-converting enzyme inhibitor and of a calcium channel antagonist and method for preparation and use thereof in the manufacture of a medicament for treatment of cardiovascular illness
AU2003202461A1 (en) Combination therapy of angiotensin converting enzyme inhibitor and side-effect-reduced amount of aldosterone antagonist for treatment of cardiovascular disease
PL366419A1 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares
SI1303306T1 (sl) Kombinacijska terapija z epoksi-steroidnim aldosteronskim antagonistom in betaadrenergicnim antagonistom za zdravljenje kongestivne srcne odpovedi
PL371437A1 (en) Aldosterone receptor antagonist and alpha-adrenergic modulating agent combination therapy for prevention or treatment of pathogenic conditions
AU2002308287A1 (en) Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors
GB9925970D0 (en) Treatment of pulmonary hypertension
IL145242A0 (en) Treatment of hiatial hernia
AU2003202486A1 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
GB9914589D0 (en) Diagnosis and treatment of alzheimers diease
GB0024728D0 (en) Hypertension diagnosis and treatment
PL355278A1 (en) Method of electrotherapy and appliance for electrotherapy
GB9901310D0 (en) Methods of treatment
GB9917181D0 (en) Methods of treatment

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20080303